Who are Infliximab plus methotrexate's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/infliximab-plus-methotrexate.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Infliximab plus methotrexate — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Infliximab plus methotrexate (Infliximab plus methotrexate) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: TNF-α inhibitor (monoclonal antibody) + DMARD. Area: Immunology / Rheumatology.

phase 3 TNF-α inhibitor (monoclonal antibody) + DMARD TNF-α receptor (infliximab); dihydrofolate reductase (methotrexate) Immunology / Rheumatology Small molecule Live · refreshed every 30 min

Target snapshot

Infliximab plus methotrexate (Infliximab plus methotrexate) — Helsinki University Central Hospital. Infliximab blocks tumor necrosis factor-alpha (TNF-α) to suppress inflammation, while methotrexate inhibits dihydrofolate reductase to reduce immune cell proliferation.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Infliximab plus methotrexate TARGET	Infliximab plus methotrexate	Helsinki University Central Hospital	phase 3	TNF-α inhibitor (monoclonal antibody) + DMARD	TNF-α receptor (infliximab); dihydrofolate reductase (methotrexate)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (TNF-α inhibitor (monoclonal antibody) + DMARD class)

Helsinki University Central Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Infliximab plus methotrexate — Competitive Intelligence Brief. https://druglandscape.com/ci/infliximab-plus-methotrexate. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing